The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

Nifty 50 Top Losers Stocks Today - View the stock market Top Losers Live data for NSE Nifty 50 in the duration of 1 day, 1 week, 1 month, 3 months, 6 months and 1 year on The Economic Times.